华润医药(03320)：博雅生物(300294.SZ)上半年股东应占净利润2.25亿元 同比减少28.68%

Group 1 - The core viewpoint of the article highlights the financial performance of China Resources Pharmaceutical's subsidiary, China Resources Boya Biotechnology, for the six months ending June 30, 2025, showing a total revenue of 1.008 billion RMB, which represents a year-on-year increase of 12.51% [1] - The net profit attributable to shareholders for the same period is reported at 225 million RMB, reflecting a year-on-year decrease of 28.68% [1]